|
|
| Product Name: | CY-09 | | Synonyms: | CY-09;4-[[4-Oxo-2-thioxo-3-[3-(trifluoromethyl)benzyl]thiazolidin-5-ylidene]methyl]benzoic Acid;CS-2756;4-[[4-Oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]benzoic acid;CY09;CY 09;CY-09;CY 09;CY09;(E)-4-((4-oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic acid;Benzoic acid, 4-[[4-oxo-2-thioxo-3-[[3-(trifluoromethyl)phenyl]methyl]-5-thiazolidinylidene]methyl]- | | CAS: | 1073612-91-5 | | MF: | C19H12F3NO3S2 | | MW: | 423.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1073612-91-5.mol |  |
| | CY-09 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:65.0(Max Conc. mg/mL);152.61(Max Conc. mM) | | form | A crystalline solid |
| | CY-09 Usage And Synthesis |
| Uses | CY-09, exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). CY-09 is an NLRP3 inhibitor. | | storage | Store at +4°C |
| | CY-09 Preparation Products And Raw materials |
|